Endre søk
Begrens søket
1234 51 - 100 of 173
RefereraExporteraLink til resultatlisten
Permanent link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Treff pr side
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sortering
  • Standard (Relevans)
  • Forfatter A-Ø
  • Forfatter Ø-A
  • Tittel A-Ø
  • Tittel Ø-A
  • Type publikasjon A-Ø
  • Type publikasjon Ø-A
  • Eldste først
  • Nyeste først
  • Skapad (Eldste først)
  • Skapad (Nyeste først)
  • Senast uppdaterad (Eldste først)
  • Senast uppdaterad (Nyeste først)
  • Disputationsdatum (tidligste først)
  • Disputationsdatum (siste først)
  • Standard (Relevans)
  • Forfatter A-Ø
  • Forfatter Ø-A
  • Tittel A-Ø
  • Tittel Ø-A
  • Type publikasjon A-Ø
  • Type publikasjon Ø-A
  • Eldste først
  • Nyeste først
  • Skapad (Eldste først)
  • Skapad (Nyeste først)
  • Senast uppdaterad (Eldste først)
  • Senast uppdaterad (Nyeste først)
  • Disputationsdatum (tidligste først)
  • Disputationsdatum (siste først)
Merk
Maxantalet träffar du kan exportera från sökgränssnittet är 250. Vid större uttag använd dig av utsökningar.
  • 51. Holmberg, Sören
    et al.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Wännström, Kent
    Väljarnas röst2012Rapport (Annet vitenskapelig)
  • 52.
    Isaksson, Eva
    et al.
    Karolinska Inst, Dept Clin Neurosci, Neurol, Nobels Vag 6, SE-17176 Stockholm, Sweden..
    Wester, Per
    Danderyd Hosp, Karolinska Inst, Dept Clin Sci, SE-18288 Stockholm, Sweden.;Umea Univ, Dept Publ Hlth & Clin Med, S-90187 Umea, Sweden..
    Laska, Ann Charlotte
    Danderyd Hosp, Karolinska Inst, Dept Clin Sci, SE-18288 Stockholm, Sweden..
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Fastigheter och byggande, Bygg- och fastighetsekonomi. Center for Safety Research.
    Lundström, Erik
    Uppsala Univ, Dept Clin Neurosci, Neurol, SE-75185 Uppsala, Sweden..
    Identifying important barriers to recruitment of patients in randomised clinical studies using a questionnaire for study personnel2019Inngår i: Trials, ISSN 1745-6215, E-ISSN 1745-6215, Vol. 20, nr 1, artikkel-id 618Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Many randomised controlled trials (RCT) fail to meet their recruitment goals. Study personnel play a key role in recruitment. The aim of this study was to identify successful strategies that study personnel consider to be important in patient recruitment to RCT. Methods: We constructed a questionnaire based on the literature, discussions with colleagues and our own experience as trialists. The survey was named "What is Important for Making a Study Successful questionnaire" (WIMSS-q). Our target group was the study personnel in the ongoing EFFECTS study. The questionnaire was sent out electronically to all physicians and nurses (n = 148). Success factors and barriers were divided according to patient, centre and study level, respectively. Results: Responses were received from 94% of the study personnel (139/148). The five most important factors at centre level for enhancing recruitment were that the research question was important (97%), a simple procedure for providing information and gaining consent (92%), a highly engaged local principal investigator and research nurse (both 87%), and that study-related follow-ups are practically feasible and possible to coordinate with the clinical follow-up (87%). The most significant barrier at the local centre was lack of time and resources devoted to research (72%). Important patient-related barriers were fear of side effects (35%) and language problems (30%). Conclusions: For recruitment in an RCT to be successful, the research question must be relevant, and the protocol must be simple and easy to implement in the daily routine.

  • 53. Ivert, Torbjorn
    et al.
    Dalen, Magnus
    Ander, Charlotte
    Stalesen, Ragnhild
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transportplanering, ekonomi och teknik.
    Lordkipanidze, Marie
    Hjemdahl, Paul
    Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid2017Inngår i: Thrombosis Research, ISSN 0049-3848, E-ISSN 1879-2472, Vol. 149, s. 64-69Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Introduction: Current guidelines recommend acetylsalicylic acid (ASA) treatment after coronary artery bypass grafting (CABG) to reduce thrombotic vein graft occlusion. The optimal dosage of ASA is not known. Materials and methods: Forty-two patients undergoing elective CABG were randomized to receive either ASA 75 mg or 160 mg once daily (OD) or 75 mg twice daily (BID) after the operation. Platelet function testing was performed before, and one and three months after the operation. Results: White blood cell counts increased during the initial postoperative days whereas platelet countswere initially slightly reduced after the operation but increased after one month without any major changes of mean platelet volumes. Serum thromboxane B-2 was more effectively suppressed at one and three months after the operation with ASA 75 mg BID or 160 mg OD than with 75 mg OD (p < 0.001). ASA 75 mg BID and 160 mg OD were equally effective. Adenosine diphosphate stimulated platelet aggregation in whole blood (Multiplate (R)) was increased one and three months after the operation, and this was counteracted by ASA 75 mg BID but not by 75 or 160 mg OD. Arachidonic acid-induced aggregation was more effectively inhibited by 75 mg BID or 160 mg OD compared to 75 mg OD at three months. Conclusions: Less effective inhibition of platelet activation was obtained with ASA 75 mg OD than with ASA 160mg OD or 75mg BID up to three months after CABG. Especially the latter dose is of interest for further studies of efficacy and clinical outcomes after CABG.

  • 54. Johansson, I.
    et al.
    Dahlstrom, U.
    Edner, M.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transportplanering, ekonomi och teknik.
    Ryden, L.
    Norhammar, A.
    Glycosylated haemoglobin predicts mortality in patients with heart failure and unknown diabetes: insights from the Swedish Heart Failure registry (SwedeHF)2016Inngår i: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 59, s. S532-S532Artikkel i tidsskrift (Fagfellevurdert)
  • 55.
    Johansson, I.
    et al.
    Karolinska Inst, Cardiol Unit, Dept Med K2, Stockholm, Sweden..
    Dahlstrom, U.
    Linkoping Univ, Dept Cardiol, Linkoping, Sweden.;Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden..
    Edner, M.
    Karolinska Inst, Cardiol Unit, Dept Med K2, Stockholm, Sweden..
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för trafikforskning, CTR.
    Ryden, L.
    Karolinska Inst, Cardiol Unit, Dept Med K2, Stockholm, Sweden..
    Norhammar, A.
    Karolinska Inst, Cardiol Unit, Dept Med K2, Stockholm, Sweden..
    Random plasma glucose predicts long-term mortality in patients with heart failure without previously known diabetes - insights from the Swedish heart failure registry (SwedeHF)2018Inngår i: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 39, s. 224-225Artikkel i tidsskrift (Annet vitenskapelig)
  • 56. Johansson, I.
    et al.
    Dahlström, U.
    Edner, M.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transportplanering, ekonomi och teknik.
    Ryden, L.
    Norhammar, A.
    Glycosylated haemoglobin predicts mortality in patients with heart failure and unknown diabetes: insights from the Swedish heart failure registry (SwedeHF)2016Inngår i: EUROPEAN HEART JOURNAL, ISSN 0195-668X, Vol. 37, s. 733-733Artikkel i tidsskrift (Fagfellevurdert)
  • 57. Johansson, I.
    et al.
    Dahlström, U.
    Edner, M.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transportplanering, ekonomi och teknik.
    Rydén, L.
    Norhammar, A.
    Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure2016Inngår i: Journal of the American College of Cardiology, ISSN 0735-1097, E-ISSN 1558-3597, Vol. 68, nr 13, s. 1404-1416Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background Heart failure (HF) is a common and serious complication in type 2 diabetes mellitus (T2DM). The prognosis of ischemic HF and impact of revascularization in such patients have not been investigated fully in a patient population representing everyday practice. Objectives This study examined the impact of ischemic versus nonischemic HF and previous revascularization on long-term prognosis in an unselected population of patients with and without T2DM. Methods Patients stratified by diabetes status and ischemic or nonischemic HF and history of revascularization in the Swedish Heart Failure Registry (SwedeHF) from 2003 to 2011 were followed up for mortality predictors and longevity. A propensity score analysis was applied to evaluate the impact of previous revascularization. Results Among 35,163 HF patients, those with T2DM were younger, and 90% had 1 or more associated comorbidities. Ischemic heart disease (IHD) occurred in 62% of patients with T2DM and 47% of those without T2DM, of whom 53% and 48%, respectively, had previously undergone revascularization. T2DM predicted mortality regardless of the presence of IHD, with adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of 1.40 (1.33 to 1.46) and 1.30 (1.22 to 1.39) in those with and without IHD, respectively. Patients with both T2DM and IHD had the highest mortality, which was further accentuated by the absence of previous revascularization (adjusted HR: 0.82 in favor of such treatment; 95% CI: 0.75 to 0.91). Propensity score adjustment did not change these results (HR: 0.87; 95% CI: 0.78 to 0.96). Revascularization did not abolish the impact of T2DM, which predicted mortality in those with (HR: 1.36; 95% CI: 1.24 to 1.48) and without (HR: 1.45; 95% CI: 1.33 to 1.56) a history of revascularization. Conclusions Ninety percent of HF patients with T2DM have preventable comorbidities. IHD in patients with T2DM had an especially negative influence on mortality, an impact that was beneficially influenced by previous revascularization.

  • 58. Johansson, I.
    et al.
    Edner, M.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Dahlstrom, U.
    Ryden, L.
    Norhammar, A.
    Diabetes mellitus, a serious co-morbidity especially in younger heart failure patients: A report from the Swedish Heart Failure Registry (RiksSvikt)2012Inngår i: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 33, s. 640-640Artikkel i tidsskrift (Annet vitenskapelig)
  • 59. Johansson, I.
    et al.
    Edner, M.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transportplanering, ekonomi och teknik.
    Dahlstrom, U.
    Ryden, L.
    Norhammar, A.
    Impact of diabetes mellitus on heart failure with reduced ejection fraction: a Swedish registry based analysis2015Inngår i: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 36, s. 877-877Artikkel i tidsskrift (Annet vitenskapelig)
  • 60. Johansson, I.
    et al.
    Edner, M.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Dahlstrom, U.
    Ryden, L.
    Norhammar, A.
    Women with heart failure and diabetes are at increased risk for mortality compared to men with and women without diabetes2012Inngår i: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 33, s. 178-178Artikkel i tidsskrift (Annet vitenskapelig)
  • 61. Johansson, I.
    et al.
    Edner, M.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Dahlström, U.
    Rydén, L.
    Norhammar, A.
    Impact of diabetes mellitus on long-term prognosis in patients with preserved heart failure - a report from the Swedish Heart Failure Registry (S-HFR)2014Inngår i: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 35, s. 334-335Artikkel i tidsskrift (Annet vitenskapelig)
  • 62. Johansson, I.
    et al.
    Edner, M.
    Ryden, L.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för trafikforskning, CTR.
    Dahlstrom, U.
    Norhammar, A.
    Impact of diabetes mellitus on long-term prognosis in patients with preserved heart failure: a report from the Swedish Heart Failure Registry (S-HFR)2014Inngår i: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 57, s. S25-S25Artikkel i tidsskrift (Annet vitenskapelig)
  • 63.
    Johansson, Isabelle
    et al.
    Karolinska Univ Hosp Solna, Stockholm, Sweden.;Karolinska Inst, Dept Med K2, Cardiol Unit, Stockholm, Sweden..
    Dahlstrom, Ulf
    Linkoping Univ, Dept Cardiol, Linkoping, Sweden.;Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden..
    Edner, Magnus
    Karolinska Univ Hosp Solna, Stockholm, Sweden.;Karolinska Inst, Dept Med K2, Cardiol Unit, Stockholm, Sweden..
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Fastigheter och byggande, Bygg- och fastighetsekonomi.
    Ryden, Lars
    Karolinska Univ Hosp Solna, Stockholm, Sweden.;Karolinska Inst, Dept Med K2, Cardiol Unit, Stockholm, Sweden..
    Norhammar, Anna
    Karolinska Univ Hosp Solna, Stockholm, Sweden.;Karolinska Inst, Dept Med K2, Cardiol Unit, Stockholm, Sweden.;Capio St Gorans Hosp, Stockholm, Sweden..
    Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function2018Inngår i: Diabetes & Vascular Disease Research, ISSN 1479-1641, E-ISSN 1752-8984, Vol. 15, nr 6, s. 494-503Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Objective: To study the characteristics and prognostic implications of type 2 diabetes in different heart failure entities from a nationwide perspective. Methods: This observational study comprised 30,696 heart failure patients prospectively included in the Swedish Heart Failure Registry (SwedeHF) 2003-2011 from specialist care, with mortality information available until December 2014. Patients were categorized into three heart failure entities by their left ventricular ejection fraction (heart failure with preserved ejection fraction: > 50%, heart failure with mid-range ejection fraction: 40%-49% and heart failure with reduced ejection fraction: <40%). All-cause mortality stratified by type 2 diabetes and heart failure entity was studied by Cox regression. Results: Among the patients, 22% had heart failure with preserved ejection fraction, 21% had heart failure with mid-range ejection fraction and 57% had heart failure with reduced ejection fraction. The proportion of type 2 diabetes was similar, approximate to 25% in each heart failure entity. Patients with type 2 diabetes and heart failure with preserved ejection fraction were older, more often female and burdened with hypertension and renal impairment compared with heart failure with mid-range ejection fraction and heart failure with reduced ejection fraction patients among whom ischaemic heart disease was more common. Type 2 diabetes remained an independent mortality predictor across all heart failure entities after multivariable adjustment, somewhat stronger in heart failure with left ventricular ejection fraction below 50% (hazard ratio, 95% confidence interval; heart failure with preserved ejection fraction: 1.32 [1.22-1.43], heart failure with mid-range ejection fraction: 1.51 [1.39-1.65], heart failure with reduced ejection fraction: 1.46 [1.39-1.54]; p-value for interaction, p = 0.0049). Conclusion: Type 2 diabetes is an independent mortality predictor across all heart failure entities increasing mortality risk by 30%-50%. In type 2 diabetes, the heart failure with mid-range ejection fraction entity resembles heart failure with reduced ejection fraction in clinical characteristics, risk factor pattern and prognosis.

  • 64. Johansson, Isabelle
    et al.
    Dahlström, Ulf
    Edner, Magnus
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transportplanering, ekonomi och teknik.
    Rydén, Lars
    Norhammar, Anna
    Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes2015Inngår i: Heart, ISSN 1355-6037, E-ISSN 1468-201X, Vol. 101, nr 14, s. 1139-1148Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Objective To test the hypothesis that risk factor pattern, treatment and prognosis differ between men and women with heart failure (HF) with and without diabetes in the Swedish Heart Failure Registry. Methods Patients with (n=8809) and without (n=27 465) type 2 diabetes (T2DM) included in the Swedish Heart Failure Registry (2003-2011) were followed for mortality during a median follow-up of 1.9 years (range 0-8.7 years). All-cause mortality, differences in background and HF characteristics were analysed in women and men with and without T2DM and with a special regard to different age groups. Results Of 36 274 patients, 24% had T2DM and 39% were women. In patients with T2DM, women were older than men (78 years vs 73 years), more frequently had hypertension, renal dysfunction and preserved ventricular function. Regardless of T2DM status, women with reduced ventricular function, compared with their male counterparts, were less frequently offered, for example, ACE inhibitors/angiotensin receptor II blockers (ARB). Absolute mortality was 48% in women with T2DM, 40% in women without; corresponding male mortality rates were 43% and 35%, respectively. Kaplan-Meier curves revealed shorter longevity in women with T2DM but female sex did not remain a significant mortality predictor following adjustment (OR 95% CI 0.90; 0.79 to 1.03). In those without T2DM, women compared with men lived longer; this pattern remained after adjustment (OR 0.72; 0.66 to 0.78). T2DM was a stronger predictor of mortality in women (OR 1.72; 1.53 to 1.94) than in men (OR 1.47; 1.34 to 1.61). Conclusions T2DM is a strong mortality predictor in men and women with HF, somewhat stronger in women. The shorter survival time in women with T2DM and HF related to comorbidities rather than sex per se. Evidence-based management was less prevalent in women. Mechanisms behind these findings remain incompletely understood and need further attention.

  • 65. Johansson, Isabelle
    et al.
    Edner, Magnus
    Dahlström, Ulf
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Trafik och logistik.
    Rydén, Lars
    Norhammar, Anna
    Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management?: An observational study from the Swedish Heart Failure Registry2014Inngår i: European Journal of Heart Failure, ISSN 1388-9842, E-ISSN 1879-0844, Vol. 16, nr 4, s. 409-418Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Aims To analyse the long-term outcome, risk factor panorama, and treatment pattern in patients with heart failure (HF) with and without type 2 diabetes (T2DM) from a daily healthcare perspective. Methods and results Patients with (n = 8809) and without (n = 27 465) T2DM included in the Swedish Heart Failure Registry (S-HFR) 2003-2011 due to a physician-based HF diagnosis were prospectively followed for long-term mortality (median follow-up time: 1.9 years, range 0-8.7 years). Left ventricular function expressed as EF did not differ between patients with and without T2DM. Survival was significantly shorter in patients with T2DM, who had a median survival time of 3.5 years compared with 4.6 years (P < 0.0001). In subjects with T2DM. unadjusted and adjusted odds ratios (ORs) for mortality were 1.37 [95% confidence interval (CI) 1.30-1.44) and 1.60 (95% CI 1.50-1.71), and T2DM predicted mortality in all age groups. Ischaemic heart disease was an important predictor for mortality (OR 1.68, 95% CI 1.47-1.94), more abundant in patients with T2DM (59% vs. 45%) among whom only 35% had been subjected to coronary angiography and 32% to revascularization. Evidence-based pharmacological HF treatment was somewhat more extensive in patients with T2DM. Conclusion The combination of T2DM and HF seriously compromises long-term prognosis. Ischaemic heart disease was identified as one major contributor; however, underutilization of available diagnostic and therapeutic facilities for ischaemic heart disease was obvious and may be an important area for future improvement in patients with T2DM and HF.

  • 66. Kahan, T.
    et al.
    Forslund, L.
    Held, C.
    Björkander, I.
    Billing, E.
    Eriksson, S. V.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Rehnqvist, N.
    Hjemdahl, P.
    Risk prediction in stable angina pectoris2013Inngår i: European Journal of Clinical Investigation, ISSN 0014-2972, E-ISSN 1365-2362, Vol. 43, nr 2, s. 141-151Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Although stable angina pectoris often carries a favourable prognosis, it remains important to identify patients with an increased risk of cardiovascular (CV) complications. Many new markers of disease activity and prognosis have been described. We evaluated whether common and easily accessible markers in everyday care provide sufficient prognostic information. Materials and methods: The Angina Pectoris Prognosis Study in Stockholm treated 809 patients (248 women) with stable angina pectoris with metoprolol or verapamil double blind during a median follow-up of 3·4 years, with a registry-based extended follow-up after 9·1 years. Clinical and mechanistic variables, including lipids and glucose, renal function, ambulatory and exercise-induced ischaemia, heart rate variability, cardiac and vascular ultrasonography, and psychosocial variables were included in an integrated analysis. Main outcome measures were nonfatal myocardial infarction (MI) and CV death combined. Results: In all, 139 patients (18 women) suffered a main outcome. Independent predictive variables were (odds ratio [95% confidence intervals]), age (1·04 per year [1·00;1·08], P = 0·041), female sex (0·33 [0·16;0·69], P = 0·001), fasting blood glucose (1.29 per mM [1.14; 1.46], P &lt; 0·001), serum creatinine (1·02 per μM [1·00;1·03], P &lt; 0·001) and leucocyte counts (1·21 per 106 cells/L [1·06;1·40], P = 0·008). Smoking habits, lipids and hypertension or a previous MI provided limited additional information. Impaired fasting glucose was as predictive as manifest diabetes and interacted adversely with serum creatinine. Sexual problems were predictive among men. Conclusions: Easily accessible clinical and demographic variables provide a good risk prediction in stable angina pectoris. Impaired glucose tolerance and an elevated serum creatinine are particularly important.

  • 67. Kjellstrom, B.
    et al.
    Ekstrand, E.
    Gustafsson, A.
    Nygren, A.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transportplanering, ekonomi och teknik.
    Ryden, L.
    Asberg, M.
    Symptoms of depression and exhaustion and their relation to myocardial infarction and periodontitis2016Inngår i: European Journal of Cardiovascular Nursing, ISSN 1474-5151, E-ISSN 1873-1953, Vol. 15, s. S96-S97Artikkel i tidsskrift (Annet vitenskapelig)
  • 68. Ledén, Lars
    et al.
    Claesson, Å.
    Gårder, P.
    Näsman, Per
    KTH, Tidigare Institutioner                               , Infrastruktur.
    Pulkkinen, U.
    Thedéen, Torbjörn
    Metodik för före-/efterstudier: tillämpat på cyklisters trafiksäkerhet1997Rapport (Annet vitenskapelig)
    Abstract [sv]

    I denna studie utvecklas och tillämpas metodiken för före/efter studier för att skatta effekten på cyklisters säkerhet av att höja upp cykelöverfarter 3-12 cm över körbanenivån. Fem ombyggda korsningar av varierande utförande studerades. Motriktad cykeltrafik mot tillåten riktning var inte särskilt vanligt. Cykelflödet mättes före och efter, vilket visar att de nybyggda cykellederna attraherade 50 procent mer cyklister. Skattning av riskförändringen gjordes med tre metoder, enligt enkäter med cyklister och experter samt enligt en kvantitativ expertmodell. De tre metoderna gav smastämmiga resultat, säkerheten för cyklisterna hade förbättrats med 30 - 50 procent.

  • 69. Lindberg, Erik
    et al.
    Thedéen, Torbjörn
    Näsman, Per
    KTH, Tidigare Institutioner                               , Infrastruktur.
    Riskanalyser/riskvärdering inom järnvägsområdet1993Rapport (Annet vitenskapelig)
  • 70. Liwing, J
    et al.
    Uttervall, K
    Andreasson, J
    Aschan, J
    Näsman, P
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Nahi, H
    The best response during the 1st line of treatment is strongly correlated to longer time to progression in real life multiple myeloma patients2011Konferansepaper (Annet vitenskapelig)
  • 71. Liwing, J
    et al.
    Uttervall, K
    Näsman, P
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Aschan, J
    Andreasson, J.
    Gruber, A
    Nahi, H
    Novel agents are beneficial for real life patients with multiple myeloma not eligible for high dose treatment2011Konferansepaper (Annet vitenskapelig)
  • 72. Liwing, J
    et al.
    Uttervall, K
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS.
    Andreasson, J
    Johansson, P
    Aschan, J
    Nahi, H
    Is Multiple Myeloma a Chronic Disease?2012Konferansepaper (Annet vitenskapelig)
  • 73.
    Liwing, J.
    et al.
    Janssen AB, Sollentuna, Sweden..
    Uttervall, K.
    Karolinska Inst, Huddinge, Sweden..
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för trafikforskning, CTR.
    Andreasson, J.
    Karolinska Inst, Huddinge, Sweden..
    Johansson, P.
    NU Hosp Org, Dept Internal Med, Uddevalla, Sweden..
    Aschan, J.
    Janssen AB, Sollentuna, Sweden..
    Nahi, H.
    Karolinska Inst, Huddinge, Sweden..
    Is multiple myeloma a chronic disease?2012Inngår i: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 97, s. 345-346Artikkel i tidsskrift (Annet vitenskapelig)
  • 74. Liwing, Johan
    et al.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS.
    Kernell, H.
    Gagnon, D.D.
    Wu, Y.
    Cost-effectiveness modelling of epoetin alfa and darbepoetin alfa in the treatment of chemotherapy-related anaemia in Sweden2010Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 13, nr 3, s. A38-A38Artikkel i tidsskrift (Annet vitenskapelig)
  • 75. Liwing, Johan
    et al.
    Uttervall, Katarina
    Lund, Johan
    Aldrin, Anders
    Blimark, Cecilie
    Carlson, Kristina
    Enestig, Jon
    Flogegård, Max
    Forsberg, Karin
    Gruber, Astrid
    Kviele, Helene Haglöf
    Johansson, Peter
    Lauri, Birgitta
    Mellqvist, Ulf-Henrik
    Swedin, Agneta
    Svensson, Magnus
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS.
    Alici, Evren
    Gahrton, Gösta
    Aschan, Johan
    Nahi, Hareth
    Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population2014Inngår i: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 164, nr 5, s. 684-693Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    The outcome for multiple myeloma patients has improved since the introduction of bortezomib, thalidomide and lenalidomide. However, studies comparing new and conventional treatment include selected patient groups. We investigated consecutive patients (n = 1638) diagnosed in a defined period and compared survival with a gender- and age-matched cohort Swedish population (n = 9 340 682). Median overall survival for non-high-dose treated patients was 2.8 years. The use of bortezomib, thalidomide or lenalidomide in first line therapy predicted a significantly longer overall survival (median 4.9 years) compared to conventional treatment (2.3 years). Among non-high-dose treated patients receiving at least 2 lines with bortezomib, thalidomide or lenalidomide, 69% and 63% have survived at 3 and 5 years as compared to 48% and 22% with conventional drugs and 88% and 79% in the matched cohort populations, respectively. The median overall survival in high-dose treated patients was 6.9 years. Of these patients, 84% survived at 3 years and 70% at 5 years as compared to 98% and 95% in the matched cohort population. Overall survival in the best non-high-dose treated outcome group is closing the gap with the matched cohort. Upfront use of new drugs is clearly better than waiting until later lines of treatment.

  • 76. Lundstrom, Erik
    et al.
    Isaksson, Eva
    Wester, Per
    Laska, Ann-Charlotte
    Näsman, Per
    KTH.
    Enhancing Recruitment Using Teleconference and Commitment Contract (ERUTECC): study protocol for a randomised, stepped-wedge cluster trial within the EFFECTS trial2018Inngår i: Trials, ISSN 1745-6215, E-ISSN 1745-6215, Vol. 19, artikkel-id 14Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Many randomised controlled trials (RCTs) fail to meet their recruitment goals in time. Trialists are advised to include study recruitment strategies within their trials. EFFECTS is a Swedish, academic-led RCT of fluoxetine for stroke recovery. The trial's primary objective is to investigate whether 20 mg fluoxetine daily compared with placebo for 6 months after an acute stroke improves the patient's functional outcome. The first patient was included on 20 October 2014 and, as of 31 August 2017, EFFECTS has included 810 of planned 1500 individuals. EFFECTS currently has 32 active centres. The primary objective of the ERUTECC (Enhancing Recruitment Using Teleconference and Commitment Contract) study is to investigate whether a structured teleconference re-visit with the study personnel at the centres, accompanied by a commitment contract, can enhance recruitment by 20% at 60 days post intervention, compared with 60 days pre-intervention, in an ongoing RCT. Methods: ERUTECC is a randomised, stepped-wedge cluster trial embedded in EFFECTS. The plan is to start ERUTECC with a running-in period of September 2017. The first intervention is due in October 2017, and the study will continue for 12 months. We are planning to intervene at all active centres in EFFECTS, except the five top recruiting centres (n=27). The rationale for not intervening at the top recruiting centres is that we believe they have reached their full potential and the intervention would be too weak for them. The hypothesis of this study is that a structured teleconference re-visit with the study personnel at the centres, accompanied by a commitment contract, can enhance recruitment by 20% 60 days post intervention, compared to 60 days pre-intervention, in an ongoing RCT. Discussion: EFFECTS is a large, pragmatic RCT of stroke in Sweden. Results from the embedded ERUTECC study could probably be generalised to high-income Western countries, and is relevant to trial management and could improve trial management in the future. It might also be useful in clinical settings outside the field of stroke.

  • 77. Lundström, B
    et al.
    Näsman, P
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS.
    KTHs Doktorandspegel 20072007Rapport (Annet vitenskapelig)
  • 78. Lundström, E
    et al.
    Isaksson, E
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS.
    Wester, P
    Laska, A-C
    SWAT 58: Enhancing Recruitment Using Teleconference and Commitment Contract (ERUTECC).2017Inngår i: The Northern Ireland Network for Trials Methodology ResearchArtikkel i tidsskrift (Annet vitenskapelig)
  • 79. Lundström, E
    et al.
    Isaksson, E
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS.
    Wester, P
    Laska, A-C
    Fransén-Dahlin, Å
    SWAT 50: Comparison of the small modified Rankin Scale questionnaire with face-to-face modified Rankin Scale.2017Inngår i: The Northern Ireland Network for Trials Methodology ResearchArtikkel i tidsskrift (Annet vitenskapelig)
  • 80. Mattsson, P
    et al.
    Näsman, P
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Ökade resurser till forskarutbildning1992Inngår i: Universitetsläraren, ISSN 0282-4973, nr 2Artikkel i tidsskrift (Annet (populærvitenskap, debatt, mm))
  • 81. Mattsson, P
    et al.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS.
    Kompetensväxlingsprojekt 2002/08: Expertrapport2008Rapport (Annet vitenskapelig)
  • 82. Murray, V
    et al.
    Gustavsson, P
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transporter och samhällsekonomi (stängd 20110301), Säkerhetsforskning (stängd 20110301).
    Mårtensson, B
    Symptomprofil vid två typer av poststroke depression och jämförelse mellan egentlig depression efter stroke med den vid ”psykiatrisk” depression2007Konferansepaper (Fagfellevurdert)
  • 83. Murray, V.
    et al.
    von Arbin, M.
    Bartfai, A.
    Berggren, A. L.
    Landtblom, A. M.
    Lundmark, J.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transporter och samhällsekonomi, Säkerhetsforskning.
    Olsson, J. E.
    Samuelsson, M.
    Terent, A.
    Varelius, R.
    Asberg, M.
    Martensson, B.
    Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression2005Inngår i: Journal of Clinical Psychiatry, ISSN 0160-6689, E-ISSN 1555-2101, Vol. 66, nr 6, s. 708-716Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Poststroke depression is a frequent condition and important to treat. The aim of this trial was to study the efficacy and tolerability of sertraline. Method: In 4 Swedish stroke centers, 123 patients (aged 70.7 +/- 9.9 years) were enrolled during the period September 1998 to January 2001 in a randomized, double-blind, placebo-controlled 26-week trial, at a mean of 128 +/- 97 days (range, 3-375 days) after stroke, if they fulfilled DSM-IV criteria of major depressive episode (N = 76) or minor depressive disorder (N = 47). The primary efficacy variable was a changed in depression assessed by the Montgomery-Asberg Depression Rating Scale. The Emotional Distress Scale (EDS) was administered and the occurrence of emotionalism and quality of life (QoL) were assessed, as well as neurologic recovery. Efficacy analyses were intention-to-treat, short-term (week 6) and long-term (week 26). Results: Of the 123 patients, 62 were treated with sertraline (50-100 mg/day) and 61 with placebo. Both groups improved substantially, with no differences between the treatments, either for major depressive episode or minor depressive disorder, or for short- or long-term antidepressant effect and neurologic outcome. EDS revealed a better outcome with sertraline at week 6 (p <.05). At week 26, the improvement in QoL was better in sertraline patients (p <.05) and there was a trend for emotionalism (p =.07). No serious side effects were seen. Conclusion: Poststroke depression as measured by a conventional depression rating scale improved over time irrespective of treatment. Positive effects specific to sertraline were identified in emotional distress, emotionalism, and QoL. The study indicates that poststroke emotional reactions comprise depression and other domains susceptible to pharmacologic therapy.

  • 84. Nahi, H
    et al.
    Liwing, J
    Näsman, P
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Uttervall, K
    Paul, E
    Andreasson, J
    Aschan, J
    Having a good response in front line improves the likelihood of having a good response in second line in real life multiple myeloma patients2011Konferansepaper (Annet vitenskapelig)
  • 85. Nahi, H
    et al.
    Liwing, J
    Uttervall, K
    Andreasson, J
    Näsman, P
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Aschan, J
    Better responses and longer TTP translates into longer overall survival in real life multiple myeloma patients2011Konferansepaper (Annet vitenskapelig)
  • 86. Nahi, H
    et al.
    Liwing, J
    Uttervall, K
    Andreasson, J
    Näsman, P
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Gruber, A
    Aschan, J
    Real life high dose treated patients benefits from novel agents2011Konferansepaper (Annet vitenskapelig)
  • 87. Nahi, Hareth
    et al.
    Liwing, Johan
    Aldrin, Anders
    Andreasson, Johan
    Blimark, Cecilie
    Carlson, Kristina
    Enestig, Jon
    Flogegard, Max
    Forsberg, Karin
    Gruber, Astrid
    Johansson, Peter
    Kviele, Helene
    Lauri, Birgitta
    Mellqvist, Ulf-Henrik
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Swedin, Agneta
    Svensson, Magnus
    Uttervall, Katarina
    Aschan, Johan
    Is Multiple Myeloma a Chronic Disease?: A Population Based Study Comparing 1843 Patients to a Matched Swedish Population2012Inngår i: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 120, nr 21Artikkel i tidsskrift (Annet vitenskapelig)
  • 88. Nahi, Hareth
    et al.
    Liwing, Johan
    Uttervall, Katarina
    Andreasson, Johan
    Gruber, Astrid
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Aschan, Johan
    Follow-up of Real Life Treated Multiple Myeloma Patients: Response, Disease Progression and Overall Survival2011Inngår i: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 118, nr 21, s. 1683-1683Artikkel i tidsskrift (Annet vitenskapelig)
  • 89. Nilsson, Caroline
    et al.
    Linde, Annika
    Montgomery, Scott M.
    Gustafsson, Liselotte
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transporter och samhällsekonomi, Säkerhetsforskning.
    Blomberg, Marta Troye
    Lilja, Gunnar
    Does early EBV infection protect against IgE sensitization?2005Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 116, nr 2, s. 438-444Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: There is indirect evidence that an increased infectious burden is associated with a decreased prevalence of IgE-mediated allergy during childhood. Objective: To determine whether there is a relation between the serostatus of 13 different viruses and parentally reported infections and IgE sensitization in 2-year-old children. To investigate whether there is an interaction between cytomegalovirus (CMV) and Epstein-Barr virus (EBV) in relation to IgE sensitization. Methods: A total of 246 infants were followed prospectively to 2 years of age with clinical examinations, skin prick test, and specific IgE analyses and through analysis of seropositivity against adenovirus, influenza, parainfluenza, respiratory syncytial virus, CMV, EBV, herpes simplex virus, human herpesvirus 6, and varicella-zoster virus. Results: There was some evidence that IgE sensitization (24%) tended to be more common among children who were seropositive against few compared with children who were seropositive against many viruses, but this was not statistically significant, and there was no consistent trend across the groups. IgE sensitization was statistically significantly less prevalent at 2 years of age among infants who were seropositive against EBV but not other viruses (adjusted odds ratio, 0.34; 95% CI, 0.14-0.86). The interaction of seropositivity against both CMV and EBV antibodies indicated a further reduction in the risk for IgE sensitization (adjusted odds ratio for interaction, 0.10; 95% CI, 0.01-0.92), indicating effect modification associated with seropositivity against CMV. Conclusion: Our results indicate that acquisition of EBV infection during the first 2 years of life is associated with a reduced risk of IgE sensitization, and this effect is enhanced by CMV coinfection.

  • 90. Nilvér, K
    et al.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS.
    Algers, S
    Mattsson, L-G
    KTH - nya blivande medlemmar i KCBU, presentation av KTHs verksamhet2012Konferansepaper (Annet vitenskapelig)
  • 91.
    Nordendahl, E.
    et al.
    Karolinska Inst, Dept Dent Med, Stockholm, Sweden..
    Gustafsson, A.
    Karolinska Inst, Dept Dent Med, Stockholm, Sweden..
    Norhammar, A.
    Karolinska Inst, Dept Med, Stockholm, Sweden.;Capio St Gorans Hosp, Stockholm, Sweden..
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för trafikforskning, CTR.
    Ryden, L.
    Karolinska Inst, Dept Med, Stockholm, Sweden..
    Kjellstrom, B.
    Karolinska Inst, Dept Med, Stockholm, Sweden..
    Severe Periodontitis Is Associated with Myocardial Infarction in Females2018Inngår i: Journal of Dental Research, ISSN 0022-0345, E-ISSN 1544-0591, Vol. 97, nr 10, s. 1114-1121Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    The aim of the present study was to test the hypothesis that there is a sex difference in the association between periodontitis (PD) and a first myocardial infarction (MI). The analysis in the case-control study was based on 785 patients (147 females and 638 males) with a first MI and 792 matched controls (147 females and 645 males), screened for cardiovascular risk factors and subjected to a panoramic dental X-ray. Periodontal status was defined by alveolar bone loss and diagnosed as no PD (>= 80% remaining alveolar bone), mild to moderate PD (66% to 79%), or severe PD (<66%). Logistic regression was used when analyzing PD as a risk factor for MI, adjusting for age, smoking, diabetes, education, and marital status. The mean age was 64 +/- 7 y for females and 62 +/- 8 y for males. Severe PD was more common in female patients than female controls (14 vs. 4%, P = 0.005), with an increased risk for severe PD among female patients with a first MI (odds ratio [OR] = 3.92, 95% confidence interval [CI] = 1.53 to 10.00, P = 0.005), which remained (OR = 3.72, 95% CI = 1.24 to 11.16, P = 0.005) after adjustments. Male patients had more severe PD (7% vs. 4%; P = 0.005) than male controls and an increased risk for severe PD (OR = 1.88, 95% CI = 1.14 to 3.11, P = 0.005), but this association did not remain following adjustment (OR = 1.67, 95% CI = 0.97 to 2.84, NS). Severe PD was associated with MI in both females and males. After adjustments for relevant confounders, this association did, however, remain only in females. These data underline the importance of considering poor dental health when evaluating cardiovascular risk, especially in females.

  • 92. Norhammar, A.
    et al.
    Johansson, I.
    Edner, M.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för trafikforskning, CTR.
    Dahlstrom, U.
    Ryden, L.
    Impact of diabetes mellitus on long-term prognosis in patients with ischaemic heart failure: a report from the Swedish Heart Failure Registry (S-HFR)2014Inngår i: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 57, s. S24-S25Artikkel i tidsskrift (Annet vitenskapelig)
  • 93. Norhammar, A.
    et al.
    Johansson, I.
    Edner, M.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Dahlström, U.
    Rydén, L.
    Impact of diabetes mellitus on long-term prognosis in patients with ischemic heart failure - a report from the Swedish Heart Failure Registry (S-HFR)2014Inngår i: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 35, s. 141-142Artikkel i tidsskrift (Annet vitenskapelig)
  • 94. Norhammar, A.
    et al.
    Kjellstrom, B.
    Habib, N.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transportplanering, ekonomi och teknik.
    Gustafsson, A.
    Karolinska Inst, Dent Med, Stockholm, Sweden..
    Ryden, L.
    Karolinska Inst, Dept Med, Cardiol Unit, Karolinska Univ Hosp, Stockholm, Sweden..
    Previously unknown glucose abnormalities are common in individuals with periodontitis, especially in those with a previous myocardial infarction2015Inngår i: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 58, s. S564-S565Artikkel i tidsskrift (Annet vitenskapelig)
  • 95. Norhammar, A.
    et al.
    Kjellstrom, B.
    Habib, N.
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transportplanering, ekonomi och teknik.
    Gustafsson, A.
    Ryden, L.
    Previously unknown glucose disturbances are common among individuals with periodontitis, especially in those with a previous myocardial infarction2015Inngår i: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 36, s. 115-116Artikkel i tidsskrift (Annet vitenskapelig)
  • 96.
    Norhammar, A.
    et al.
    Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
    Kjellström, B.
    Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
    Habib, N.
    Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
    Gustafsson, A.
    Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
    Klinge, B.
    Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
    Nygren, Å.
    Department of Clinical Sciences, Danderyds Hospital, Karolinska Institutet, Stockholm, Sweden.
    Näsman, Per
    KTH, Tidigare Institutioner (före 2005), Infrastruktur. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för trafikforskning, CTR.
    Svenungsson, E.
    Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
    Rydén, L.
    Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
    Undetected dysglycemia is an important risk factor for two common diseases, myocardial infarction and periodontitis: A report from the ParokRank study. Diabetes care 2019;42:1504-15112020Inngår i: Diabetes Care, Vol. 43, nr 1Artikkel i tidsskrift (Fagfellevurdert)
  • 97.
    Norhammar, Anna
    et al.
    Karolinska Inst, Dept Med, Stockholm, Sweden.;Capio St Gorans Hosp, Stockholm, Sweden..
    Kjellstroem, Barbro
    Karolinska Inst, Dept Med, Stockholm, Sweden..
    Habib, Natalie
    Karolinska Inst, Dept Med, Stockholm, Sweden..
    Gustafsson, Anders
    Karolinska Inst, Dept Dent Med, Stockholm, Sweden..
    Klinge, Bjoern
    Karolinska Inst, Dept Dent Med, Stockholm, Sweden.;Malmo Univ, Fac Odontol, Dept Periodontol, Malmo, Sweden..
    Nygren, Ake
    Karolinska Inst, Danderyds Hosp, Dept Clin Sci, Stockholm, Sweden..
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för trafikforskning, CTR.
    Svenungsson, Elisabet
    Karolinska Inst, Dept Med, Stockholm, Sweden..
    Ryden, Lars
    Karolinska Inst, Dept Med, Stockholm, Sweden..
    Response to Comment on Norhammar et al. Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care 2019;42:1504-15112020Inngår i: Diabetes Care, ISSN 0149-5992, E-ISSN 1935-5548, Vol. 43, nr 1, s. E9-E9Artikkel i tidsskrift (Fagfellevurdert)
  • 98.
    Norhammar, Anna
    et al.
    Karolinska Inst, Dept Med K2, Stockholm, Sweden. orhammar, Anna.
    Kjellström, Barbro
    Habib, Natalie
    Gustafsson, Anders
    Klinge, Björn
    Nygren, Åke
    Näsman, Per
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS.
    Svenungsson, Elisabet
    Rydén, Lars
    Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study2019Inngår i: Diabetes Care, ISSN 0149-5992, E-ISSN 1935-5548, Vol. 42, nr 8, s. 1504-1511Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    OBJECTIVE: Information on the relationship among dysglycemia (prediabetes or diabetes), myocardial infarction (MI), and periodontitis (PD) is limited. This study tests the hypothesis that undetected dysglycemia is associated with both conditions. RESEARCH DESIGN AND METHODS: The PAROKRANK (Periodontitis and Its Relation to Coronary Artery Disease) study included 805 patients with a first MI and 805 matched control subjects. All participants without diabetes (91%) were examined with an oral glucose tolerance test. Abnormal glucose tolerance (AGT) (impaired glucose tolerance or diabetes) was categorized according to the World Health Organization. Periodontal status was categorized from dental X-rays as healthy (≥80% remaining alveolar bone height), moderate (79-66%), or severe (<66%) PD. Odds ratios (ORs) and 95% CIs were calculated by logistic regression and were adjusted for age, sex, smoking, education, marital status, and explored associated risks of dysglycemia to PD and MI, respectively. RESULTS: AGT was more common in patients than in control subjects (32% vs. 19%; P < 0.001) and was associated with MI (OR 2.03; 95% CI 1.58-2.60). Undetected diabetes was associated with severe PD (2.50; 1.36-4.63) and more strongly in patients (2.35; 1.15-4.80) than in control subjects (1.80; 0.48-6.78), but not when categorized as AGT (total cohort: 1.07; 0.67-1.72). Severe PD was most frequent in subjects with undetected diabetes, and reversely undetected diabetes was most frequent in patients with severe PD. CONCLUSIONS: In this large case-control study previously undetected dysglycemia was independently associated to both MI and severe PD. In principal, it doubled the risk of a first MI and of severe PD. This supports the hypothesis that dysglycemia drives two common diseases, MI and PD.

  • 99.
    Näsman, P
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Bicycle safety: Perceived Risk Reduction at Intersections1996Konferansepaper (Fagfellevurdert)
  • 100.
    Näsman, P
    et al.
    KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Centra, Centrum för transportstudier, CTS. KTH, Skolan för arkitektur och samhällsbyggnad (ABE), Transportvetenskap, Transport- och lokaliseringsanalys.
    Eneland, M
    Ersättningsbeloppets fördelning i industribrand II 1950-19691976Rapport (Annet vitenskapelig)
1234 51 - 100 of 173
RefereraExporteraLink til resultatlisten
Permanent link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf